Financial Summary (All financials)
| In millions of CNY, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 87,606.0 | 73,667.1 | 59,241.1 | 51,178.6 | 44,437.4 | 38,178.8 | 22,802.9 | 11,712.8 |
| Revenue growth | 18.9% | 24.4% | 15.8% | 15.2% | 16.4% | 67.4% | 94.7% | 27.4% |
| Cost of goods sold | 40,635.2 | 34,683.7 | 27,685.8 | 23,832.4 | 19,394.3 | 16,515.0 | 9,399.3 | 3,261.5 |
| Gross profit | 46,970.8 | 38,983.4 | 31,555.3 | 27,346.1 | 25,043.0 | 21,663.8 | 13,403.6 | 8,451.3 |
| Gross margin | 53.6% | 52.9% | 53.3% | 53.4% | 56.4% | 56.7% | 58.8% | 72.2% |
| Sales and marketing | 12,214.2 | 10,703.8 | 6,221.1 | 6,911.7 | 5,504.6 | 4,481.8 | 2,958.2 | 1,895.0 |
| Research and development | 14,076.0 | 10,369.4 | 8,413.2 | 7,378.5 | 4,161.7 | 3,047.0 | 2,158.9 | 1,323.5 |
| General and administrative | 4,263.5 | 3,371.8 | 3,130.3 | 3,078.6 | 2,381.8 | 1,506.2 | 1,014.4 | 467.7 |
| EBIT | 16,417.1 | 14,538.4 | 13,790.7 | 9,977.3 | 12,994.9 | 12,628.9 | 7,272.1 | 4,765.1 |
| EBIT margin | 18.7% | 19.7% | 23.3% | 19.5% | 29.2% | 33.1% | 31.9% | 40.7% |
| Pre-tax income | 21,104.5 | 15,372.1 | 16,383.3 | 11,076.7 | 13,839.6 | 13,895.4 | 8,110.3 | 5,458.4 |
| Income taxes | 4,128.3 | 3,041.8 | 2,914.7 | 2,460.7 | 2,156.0 | 2,102.5 | 1,273.4 | 662.7 |
| Tax rate | 19.6% | 19.8% | 17.8% | 22.2% | 15.6% | 15.1% | 15.7% | 12.1% |
| Earnings from continuing ops | 16,856.8 | 12,062.8 | 13,275.0 | 8,291.1 | 11,542.4 | 11,604.5 | 6,735.1 | 4,834.8 |
| Earnings from discontinued ops | | | 7,962.5 | -2,138.7 | -834.5 | | | |
| Net income | 16,856.8 | 12,062.8 | 21,237.5 | 6,152.4 | 10,707.9 | 11,604.5 | 6,735.1 | 4,834.8 |
| Net margin | 19.2% | 16.4% | 35.8% | 12.0% | 24.1% | 30.4% | 29.5% | 41.3% |
| |
| Diluted EPS | $5.01 | $3.60 | $4.08 | $2.55 | $3.48 | $3.51 | $2.04 | $1.48 |
| Shares outstanding (diluted) | 3,367.5 | 3,349.8 | 3,250.0 | 3,254.7 | 3,315.5 | 3,307.1 | 3,305.2 | 3,277.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|